| [1] |
Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: a review[J]. Transl Lung Cancer Res, 2018, 7(5):537-542. doi: 10.21037/tlcr.2018.10.04.
|
| [2] |
魏波, 蔡梓凯, 卫洪波. 恶性腹膜间皮瘤[J]. 中华胃肠外科杂志, 2017, 20(11):1251-1253. doi: 10.3760/cma.j.issn.1671-0274.2017.11.009.
|
| [3] |
曾艳, 童瑞, 王翔耀, 等. 恶性腹膜间皮瘤26例临床特点及预后影响因素分析[J]. 解放军医学院学报, 2015, 36(6):559-562,567. doi: 10.3969/j.issn.2095-5227.2015.06.010.
|
| [4] |
魏思忱, 郑国启, 王志刚, 等. 沧州地区162例腹膜恶性间皮瘤临床资料回顾性分析[J]. 中华内科杂志, 2013, 52(7):599-601. doi: 10.3760/cma.j.issn.0578-1426.2013.07.018.
|
| [5] |
杜雪梅, 李鑫宝, 孟巍, 等. 恶性腹膜间皮瘤100例临床病理特征及预后分析[J]. 中国肿瘤临床, 2023, 50(8):403-410. doi: 10.12354/j.issn.1000-8179.2023.20221530.
|
| [6] |
刘佳敏, 孙建海. 恶性腹膜间皮瘤伴胸膜转移1例并文献复习[J]. 癌症进展, 2024, 22(17):1969-1971. doi: 10.11877/j.issn.1672-1535.2024.22.17.26.
|
| [7] |
Attanoos RL, Churg A, Galateau-Salle F, et al. Malignant Mesothelioma and Its Non-Asbestos Causes[J]. Arch Pathol Lab Med, 2018, 142(6):753-760. doi: 10.5858/arpa.2017-0365-RA.
pmid: 29480760
|
| [8] |
张静静, 肖华, 孙晓伟, 等. 石棉肺合并恶性腹膜间皮瘤1例[J]. 中国工业医学杂志, 2023, 36(6):507-510. doi: 10.13631/j.cnki.zggyyx.2023.06.007.
|
| [9] |
苏延冬, 刘刚, 杜雪梅, 等. 弥漫性恶性腹膜间皮瘤伴副肿瘤综合征1例报道及文献复习[J]. 肿瘤防治研究, 2022, 49(3):246-250.doi: 10.3971/j.issn.1000-8578.2022.21.0445.
|
| [10] |
Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification[J]. J Thorac Oncol, 2022, 17(5):608-622. doi: 10.1016/j.jtho.2021.12.014.
pmid: 35026477
|
| [11] |
Liu S, Staats P, Lee M, et al. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients[J]. Pathology, 2014, 46(7):604-609. doi: 10.1097/PAT.0000000000000181.
|
| [12] |
Sugarbaker PH, Welch LS, Mohamed F, et al. A review of peritoneal mesothelioma at the Washington Cancer Institute[J]. Surg Oncol Clin N Am, 2003, 12(3):605-621. doi: 10.1016/s1055-3207(03)00045-0.
pmid: 14567020
|
| [13] |
Alexander HR Jr, Li CY, Kennedy TJ. Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma[J]. Ann Surg Oncol, 2018, 25(8):2159-2164. doi: 10.1245/s10434-018-6337-5.
pmid: 29423664
|
| [14] |
王桢李, 邵雪, 张倩, 等. 恶性腹膜间皮瘤研究进展[J]. 临床荟萃, 2017, 32(9):819-823. doi: 10.3969/j.issn.1004-583X.2017.09.022.
|
| [15] |
中国抗癌协会腹膜肿瘤专业委员会, 中国抗癌协会肿瘤热疗专业委员会, 北京癌症防治学会肿瘤热疗专业委员会. 弥漫性恶性腹膜间皮瘤诊治中国专家共识[J]. 中华医学杂志, 2021, 101(36):2839-2849. doi: 10.3760/cma.j.cn112137-20210210-00405.
|
| [16] |
Grosso F, Steele N, Novello S, et al. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase Ⅱ Results From the Randomized, Placebo-Controlled LUME-Meso Trial[J]. J Clin Oncol, 2017, 35(31):3591-3600. doi: 10.1200/JCO.2017.72.9012.
|
| [17] |
Varghese S, Chen Z, Bartlett DL, et al. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma[J]. Cancer, 2011, 117(2):361-371. doi: 10.1002/cncr.25555
pmid: 20839315
|